首页> 外文期刊>Journal of diabetes research. >Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy
【24h】

Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy

机译:Ranirestat改善了具有明显糖尿病多大功能的大鼠的神经传导速度,感官感知和脑内神经纤维密度

获取原文
           

摘要

Distal sensory-motor polyneuropathy is one of the most frequent diabetic complications. However, few therapies address the etiology of neurodegeneration in the peripheral nervous systems of diabetic patients. Several metabolic mechanisms have been proposed as etiologies of this polyneuropathy. In this study, we revisited one of those mechanisms, the polyol pathway, and investigated the curative effects of a novel strong aldose reductase inhibitor, ranirestat, in streptozotocin-induced diabetic rats with preexisting polyneuropathy. Twelve weeks after the onset of diabetes, rats which had an established polyneuropathy were treated once daily with a placebo, ranirestat, or epalrestat, over 6 weeks. Before and after the treatment, nerve conduction velocities and thermal perception threshold of hindlimbs were examined. After the treatment, intraepidermal fiber density was evaluated. As an ex vivo assay, murine dorsal root ganglion cells were dispersed and cultured with or without 1?μmol/l ranirestat for 48 hours. After the culture, neurite outgrowth was quantified using immunological staining. Sensory nerve conduction velocity increased in diabetic rats treated with ranirestat (43.3±3.6?m/s) compared with rats treated with placebo (39.8±2.3). Motor nerve conduction velocity also increased in the ranirestat group (45.6±3.9) compared with the placebo group (38.9±3.5). The foot withdrawal latency to noxious heating was improved in the ranirestat group (17.7±0.6?seconds) compared with the placebo group (20.6±0.6). The decrease in the intraepidermal fiber density was significant in the diabetic placebo group (21.6±1.7/mm) but not significant in the diabetic ranirestat group (26.2±1.2) compared with the nondiabetic placebo group (30.3±1.5). Neurite outgrowth was promoted in the neurons supplemented with ranirestat (control 1446±147?μm/neuron, ranirestat 2175±149). Ranirestat improved the peripheral nervous dysfunctions in rats with advanced diabetic polyneuropathy. Ranirestat could have potential for regeneration in the peripheral nervous system of diabetic rats.
机译:远端感觉 - 电动机多变病疗法是最常见的糖尿病并发症之一。然而,很少有疗法解决了糖尿病患者外周神经系统中神经变性的病因。已经提出了几种代谢机制作为这种多肌病的病因。在这项研究中,我们重新审视了其中一种机制,多元醇途径,并研究了一种新型强醛醛糖苷还原酶抑制剂,Ranirestat在链脲佐菌素诱导的糖尿病大鼠中具有预先存在的多肌病的疗法作用。糖尿病发作后12周,每天用安慰剂,ranirestat或ePalrestat治疗既定的多肺病的大鼠,超过6周。在治疗之前和之后,检查了神经传导速度和后肢的热感性阈值。治疗后,评价胎儿纤维密度。作为前体内测定,用或没有1·μmol/ L ranirestat分散并培养小鼠背根神经节细胞48小时。在培养后,使用免疫染色量化神经突的异常。与用安慰剂处理的大鼠相比,在用Ranirestat(43.3±3.6μm/ s)处理的糖尿病大鼠中的感觉神经传导速度增加(39.8±2.3)。与安慰剂组相比,运动神经传导速度也增加了Ranirestat组(45.6±3.9)(38.9±3.5)。与安慰剂组(20.6±0.6)相比,Ranirestat组(17.7±0.6Ω秒)的脚取出潜伏期得到改善(17.7±0.6秒)。糖尿病安慰剂组(21.6±1.7 / mm)中的骨髓内纤维密度的降低均显着,但与NongiaBeticabo组(30.3±1.5)相比,糖尿病Ranirestat组(26.2±1.2)中不显着。在补充有Ranirestat的神经元中促进了神经突幼虫(对照1446±147?μm/ neuron,Ranirestat 2175±149)。 Ranirestat改善了具有晚期糖尿病多变病变的大鼠的周围神经功能障碍。 Ranirestat可能在糖尿病大鼠外周神经系统中具有再生潜力。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号